Literature DB >> 14961909

Psoriasis induced by topical imiquimod.

Jason K Wu1, Greg Siller, Geoff Strutton.   

Abstract

We report the provocation of localized psoriasis at the sites of application of topical imiquimod, possibly evolving into a generalized flare. A patient with pre-existing psoriasis that had been stable for 14 years was treated with imiquimod 5% cream daily for 6 weeks to three superficial basal cell carcinomas. During treatment one of the lesions developed severe local skin reactions necessitating rest periods, and received only 18 applications in 6 weeks. The other two lesions were treated for all 42 days. Psoriasiform changes developed at all three application sites. Nine-and-a-half weeks after completing treatment the patient developed disseminated small psoriatic lesions. Other recognized triggers of psoriasis were not identified. The psoriasis resolved slowly with conventional treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14961909     DOI: 10.1111/j.1440-0960.2004.00030.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  39 in total

Review 1.  Pattern recognition receptors in immune disorders affecting the skin.

Authors:  Heleen D de Koning; Anna Simon; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  J Innate Immun       Date:  2012-03-06       Impact factor: 7.349

Review 2.  Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.

Authors:  M Afshar; A D Martinez; R L Gallo; T R Hata
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-06-01       Impact factor: 6.166

3.  The Expression of Toll-like Receptors in Dermatological Diseases and the Therapeutic Effect of Current and Newer Topical Toll-like Receptor Modulators.

Authors:  Whitney Valins; Sadegh Amini; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-09

Review 4.  Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.

Authors:  Antona J Wagstaff; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk.

Authors:  Luigi Tortola; Esther Rosenwald; Brian Abel; Hal Blumberg; Matthias Schäfer; Anthony J Coyle; Jean-Christoph Renauld; Sabine Werner; Jan Kisielow; Manfred Kopf
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

6.  A GRHL3-regulated repair pathway suppresses immune-mediated epidermal hyperplasia.

Authors:  William M Gordon; Michael D Zeller; Rachel H Klein; William R Swindell; Hsiang Ho; Francisco Espetia; Johann E Gudjonsson; Pierre F Baldi; Bogi Andersen
Journal:  J Clin Invest       Date:  2014-10-27       Impact factor: 14.808

7.  Does imiquimod pretreatment optimize 308-nm excimer laser (UVB) therapy in psoriasis patients?

Authors:  Joselin D Tacastacas; Patricia Oyetakin-White; David C Soler; Andrew Young; Sarah Groft; Kord Honda; Kevin D Cooper; Thomas S McCormick
Journal:  Photodermatol Photoimmunol Photomed       Date:  2017-04-20       Impact factor: 3.135

8.  IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms.

Authors:  Hye-Lin Ha; Hongshan Wang; Prapaporn Pisitkun; Jin-Chul Kim; Ilaria Tassi; Wanhu Tang; Maria I Morasso; Mark C Udey; Ulrich Siebenlist
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

9.  Keratinocytes contribute intrinsically to psoriasis upon loss of Tnip1 function.

Authors:  Sirish K Ippagunta; Ruchika Gangwar; David Finkelstein; Peter Vogel; Stephane Pelletier; Sebastien Gingras; Vanessa Redecke; Hans Häcker
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-26       Impact factor: 11.205

10.  Topical heat shock protein 70 prevents imiquimod-induced psoriasis-like inflammation in mice.

Authors:  Federico G Seifarth; Julia E-M Lax; Jennifer Harvey; Paul E DiCorleto; M Elaine Husni; Unnikrishnan M Chandrasekharan; Michael Tytell
Journal:  Cell Stress Chaperones       Date:  2018-04-03       Impact factor: 3.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.